Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Owkin (Group)

Owkin is the first end-to-end TechBio company on a mission to understand complex biology and derive new multimodal biomarkers through AI. We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing federated technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular, immunity and inflammation. Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research. Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like Fidelity, GV and Bpifrance, among others. *


Period Start 2016-01-01 established
Products Industry artificial intelligence (AI) / machine learning (ML)
  Industry 2 Owkin Socrates
Person Person Clozel, Thomas (Owkin 202111 CEO + Co-Founder)
Region Region Paris
  Country France
  Street 12 Rue Martel
  City 75010 New York, NY
    Address record changed: 2024-01-05
Basic data Employees n. a.
    * Document for »About Section«: Owkin. (3/21/24). "Press Release: Owkin Expands Collaboration with Sanofi Leveraging AI for Drug Positioning in immunology".
Record changed: 2024-03-30


Picture [iito] [LSE] Business Portal 650x200px

More documents for Owkin (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top